The first ever BBSRC Diamond Professorial Fellow, Professor So Iwata, has been awarded the 2009 Aminoff Prize by the Royal Swedish Academy of Sciences for his work in the field of crystallography.
30 September, 2009
Karus Therapeutics Ltd, a company developing small-molecule drugs to treat cancer and inflammation, announced recently that it has signed an agreement to collaborate with Professor Bart Vanhaesebroeck at Queen Mary, University of London.
29 September, 2009
Scientists have uncovered what happens to biomimetic nanoparticles when they enter human cells.
28 September, 2009
Vaccine developers with insight into the latest advances will be drivers of innovation within the vaccine industry, yet there is a lack of available training courses in the field.
25 September, 2009
ID Business Services (IDBS) announced yesterday that IDBS customer Dr Martin Vanderlaan, Director, Analytical Operations at Genentech, will present ‘Implementing an Electronic Lab Notebook for a Large Bioprocess Organisation’ at IQPC’s ELN and Advanced Lab Solutions Conference in Brussels, Belgium.
25 September, 2009
AstraZeneca and Nektar Therapeutics announced recently that they have entered into a worldwide license agreement for two drug development programmes: NKTR-118, a late-stage investigational product being evaluated for the treatment of opioid-induced constipation, and the NKTR-119 programme, an early-stage programme that is intended to deliver products for the treatment of pain without constipation side-effects.
24 September, 2009
Findings could lead to new targets for drug discovery.
23 September, 2009
Cancer Research UK is set to extend its drug discovery effort by investing up to £16 million in two new Drug Discovery Programmes at the Paterson Institute for Cancer Research in Manchester and the Beatson Institute for Cancer Research in Glasgow.
22 September, 2009
Integrated chemical genetics and proteomics approach identifies new potential drug targets in Wnt pathway.
18 September, 2009
The Drug Information Association (DIA) has announced the hiring of Paul Pomerantz, MBA, CAE, as its new worldwide executive director.
17 September, 2009
Orphan drug designation ensures market exclusivity for seven to ten years after market approval.
16 September, 2009
Innovative Medicines Initiative, the public–private partnership between the European Commission and the European pharmaceutical industry (represented by EFPIA), today made its first major announcement of the success of the collaboration.
15 September, 2009
A series of iron-binding agents to prevent Alzheimer’s disease has shown promising potential for getting into brain tissue.
14 September, 2009
Further pain reduction on duloxetine shown during study’s extension phase.
14 September, 2009
Synthetic hydrogels could soon be used instead of animal tissue to test the sticking power of future medicines, if new materials described at the Royal Pharmaceutical Society’s annual event in Manchester, the British Pharmaceutical Conference, are developed further.
11 September, 2009
At least a quarter of people with heart disease don’t take vital medicines that have been prescribed to them to prevent heart attacks and strokes.
11 September, 2009
Two varieties of basil that are widely used in Ayurvedic medicine have been scientifically shown to reduce inflammation and swelling, suggesting that they could have potential in arthritis treatment.
10 September, 2009
As the 20th Drug Delivery to the Lungs (DDL) conference approaches, DDL Chairman Sandy Munro offers his view on what he anticipates to be the highlights for this year’s conference; including the aims to maintain the Drug Delivery to the Lungs (DDL) technical focus while broadening its horizons. He will also be previewing what's in store for this year's special anniversary event.
09 September, 2009
Space-age technology and crime research have combined for this new development.
09 September, 2009
AstraZeneca recently announced results from the Phase III head-to-head trial PLATO that demonstrate that ticagrelor has achieved greater efficacy in the primary endpoint, reduction of cardiovascular events, than clopidogrel.
08 September, 2009
Shire reported recently that it has completed its submission of a New Drug Application for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease, with the U.S. Food and Drug Administration.
04 September, 2009
The National Institute for Health and Clinical Excellence (NICE) recently issued guidance on the use of bevacizumab, sorafenib and temsirolimus for the treatment of renal cell carcinoma and the use of sorafenib and sunitinib for second-line treatment options for people with renal cell carcinoma.
02 September, 2009
The National Institute for Health and Clinical Excellence (NICE) recently published final guidance on the use of cetuximab for the first-line treatment of metastatic colorectal cancer.
02 September, 2009
Ablynx recently announced positive results from its Phase I study with ALX-0681, a subcutaneous formulation of its novel anti-thrombotic Nanobody® that selectively targets von Willebrand factor.
01 September, 2009